Study of the Disease Process of Lymphangioleiomyomatosis

Recruiting now

Conditions studied: Lung Disease, Pneumothorax, Tuberous Sclerosis, Lymphangioleiomyomatosis

In brief

Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. This study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy. Researchers intend to identify the proteins and genes that contribute to the process of lung destruction in affected individuals.

Key facts

Study ID

NCT00001465

Run by

National Heart, Lung, and Blood Institute (NHLBI)

People needed

2000

Starts

1995-12-18

Last updated by the study team

2026-08-10

Who can join

Age: 16 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Exclusion criteria for patients include:
• Age less than 16.
• Advanced stage of a pulmonary or a systemic illness in which the risk of the study is judged to be significant even in the absence of a clear contraindication to the procedures.
• Exclusion criteria for patients for the formal exercise study and the stress echocardiogram include patients on continuous oxygen. Patients may perform an exercise test that will assess the patient's exercise capacity with activities of daily living.

Where it is running

• National Institutes of Health Clinical Center — Bethesda, Maryland, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.